California, USA-based BioTime says that it has entered into an addendum to its agreement with Summit Pharmaceuticals International to develop Hextend (high molecular weight hydroxethyl starch) and PentaLyte (pentastarch-based synthetic plasma) for the Japanese market.
The addendum grants Summit the licenses required to permit the firm to implement an agreement with Maruishi Pharmaceutical, to seek regulatory approval and to manufacture and market Hextend in Japan. Summit will also participate in the regulatory approval process and will have the right to manufacture and market Hextend in Japan if regulatory approval is obtained.
Under its joint-development agreement with Summit, BioTime will be entitled to receive its pro rata share of the royalties and milestone payments payable by Maruishi through Summit. If Summit sells Hextend, BioTime will also be entitled to receive its pro rata share of net sales revenues.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze